Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center
Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center
复制标题
DOI：
10.1007/s00428-017-2155-6
复制
发表时间：
2017-11-01
期刊：
影响因子：
3.5
通讯作者：
Gidley, Paul W.
中科院分区：
文献类型：
--
作者：
Bell, Diana;El-Naggar, Adel K.;Gidley, Paul W.
中耳神经内分泌肿瘤极为罕见。我们回顾了中耳腺瘤性神经内分泌肿瘤（MEANTs）的治疗经验。我们检索我院1990年至2015年收治的中耳腺瘤、腺瘤性肿瘤、伴有神经内分泌分化的腺瘤性肿瘤、中耳类癌、中耳低度神经内分泌肿瘤、中耳神经内分泌癌患者的病理档案，确定有随访资料的患者14例。在此，我们回顾这些患者的病理和鉴别诊断，并讨论这些患者的治疗和随访。我们的报告增加了一系列伴有复发、淋巴结受累、远处转移和肿瘤相关死亡的MEANTs病例。我们的经验表明，尽管这些肿瘤长期以来被认为是低侵袭性肿瘤，但长期随访研究以确定这种假定的良性是有必要的。
Neuroendocrine tumors are extremely rare in the middle ear. We reviewed our institutional experience with middle ear adenomatous neuroendocrine tumors (MEANTs). We searched our institution's pathology files to identify patients treated from 1990 to 2015 who had lesions classified as middle ear adenomas, adenomatous tumors, adenomatous tumors with neuroendocrine differentiation, carcinoid tumors of the middle ear, low-grade neuroendocrine tumors of the middle ear, and neuroendocrine carcinomas of the middle ear and identified 14 such patients for whom follow-up information was available. Herein, we review the pathology and differential diagnosis of these patients' tumors and discuss the management and follow-up of these patients. Our report adds to the series cases of MEANTs with recurrences, lymph node involvement, distant metastases, and tumor-related deaths. Our experience suggests that, although these tumors have long been considered to be low-aggression neoplasms, long-term follow-up studies to ascertain this supposed benignity are warranted.